Hind Ibork
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hind Ibork has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Oualid Abboussi
Physiology and Physiopathology Team, Faculty of Sciences, Genomic of Human Pathologies Research Centre, Mohammed V University, Rabat 1014, Morocco
3 shared publications Farid Khallouki
Team of Ethnopharmacology and Pharmacognosy, Biology Department, Faculty of Sciences and Techniques Errachidia Moulay Ismail University of Meknes Errachidia Morocco
2 shared publicationsKhadija Boualam
Physiology and Physiopathology Team Faculty of Sciences, Genomic of Human Pathologies Research Centre, Mohammed V University in Rabat Rabat Morocco
2 shared publicationsKhalid Taghzouti
Physiology and Physiopathology Team Faculty of Sciences, Genomic of Human Pathologies Research Centre, Mohammed V University in Rabat Rabat Morocco
2 shared publicationsLhoussain Hajji
Bioactives, Health and Environmental Laboratory, Epigenetics Research Team Moulay Ismail University Meknes Morocco
2 shared publicationsSara El Idrissi
Physiology and Physiopathology Team Faculty of Sciences, Genomic of Human Pathologies Research Centre, Mohammed V University in Rabat Rabat Morocco
2 shared publications
Latest Publications
- Open Access
- 27 June 2026
- Published by Society of Land Measurements and Cadastre from Transylvania in Notulae Scientia Biologicae
- Vol. 18 (2)
Moroccan Cannabis sativa L. seed chloroform extract: phytochemistry, acute toxicity, and metabolic-behavioral effects in mice
Despite growing interest in the therapeutic use of Cannabis sativa L. following its legalization for medicinal purposes in 2021, the toxicity profile of its seeds remains largely underexplored in Morocco. This study aimed to characterize the phytochemical profile and acute oral toxicity of a chloroform seed extract (C/S) from Moroccan Cannabis sativa L. C/S extract (yield: 4.27 ± 0.13%) was analyzed by gas chromatography coupled with mass spectrometry (GC-MS). Acute toxicity testing was performed according to OECD Test Guideline 425: female Swiss mice (n = 5/group) received a single 2,000 mg kg⁻¹ oral dose or vehicle control, followed by 14 d monitoring of clinical signs, body weight (BW), organ weight, and serum biochemistry (ASAT/ALAT, creatinine, urea, and lipid profile). GC-MS analysis revealed 16 compounds, with octacosane (6.80%), 2-methyloctadecane (5.75%), and cannabidiol (5.32%) as the major components. No treatment-related mortality was observed (LD₅₀ > 2,000 mg kg⁻¹), and only transient signs of hypoactivity/tachycardia were noted, which resolved spontaneously within a few hours. BW gain (p = 0.154), liver/BW (p = 0.103), and kidney/BW (p = 0.406) ratios showed no significant differences. Total cholesterol was lower in the C/S group than in controls (0.82 ± 0.06 g L⁻¹ vs. 2.13 ± 0.38 g L⁻¹, p = 0.014), whereas LDL-C was higher in the C/S group (0.07 ± 0.00 g L⁻¹ vs. 0.03 ± 0.01 g L⁻¹, p = 0.002). The C/S extract demonstrated low acute toxicity under the tested conditions, supporting further safety-oriented pharmaceutical investigation of Moroccan Cannabis sativa L. seeds.
- 27 June 2026
- Published by Society of Land Measurements and Cadastre from Transylvania in Notulae Scientia Biologicae
- Vol. 18 (2)
Open AccessMoroccan Cannabis sativa L. seed chloroform extract: phytochemistry, acute toxicity, and metabolic-behavioral effects in mice
Despite growing interest in the therapeutic use of Cannabis sativa L. following its legalization for medicinal purposes in 2021, the toxicity profile of its seeds remains largely underexplored in Morocco. This study aimed to characterize the phytochemical profile and acute oral toxicity of a chloroform seed extract (C/S) from Moroccan Cannabis sativa L. C/S extract (yield: 4.27 ± 0.13%) was analyzed by gas chromatography coupled with mass spectrometry (GC-MS). Acute toxicity testing was performed according to OECD Test Guideline 425: female Swiss mice (n = 5/group) received a single 2,000 mg kg⁻¹ oral dose or vehicle control, followed by 14 d monitoring of clinical signs, body weight (BW), organ weight, and serum biochemistry (ASAT/ALAT, creatinine, urea, and lipid profile). GC-MS analysis revealed 16 compounds, with octacosane (6.80%), 2-methyloctadecane (5.75%), and cannabidiol (5.32%) as the major components. No treatment-related mortality was observed (LD₅₀ > 2,000 mg kg⁻¹), and only transient signs of hypoactivity/tachycardia were noted, which resolved spontaneously within a few hours. BW gain (p = 0.154), liver/BW (p = 0.103), and kidney/BW (p = 0.406) ratios showed no significant differences. Total cholesterol was lower in the C/S group than in controls (0.82 ± 0.06 g L⁻¹ vs. 2.13 ± 0.38 g L⁻¹, p = 0.014), whereas LDL-C was higher in the C/S group (0.07 ± 0.00 g L⁻¹ vs. 0.03 ± 0.01 g L⁻¹, p = 0.002). The C/S extract demonstrated low acute toxicity under the tested conditions, supporting further safety-oriented pharmaceutical investigation of Moroccan Cannabis sativa L. seeds.
- 8 April 2025
- Published by Wiley in Journal of Neuroscience Research
- Vol. 103 (4) , e70035
Cannabidiol‐Rich Cannabis sativa L. Extract Alleviates LPS‐Induced Neuroinflammation Behavioral Alterations, and Astrocytic Bioenergetic Impairment in Male Mice
Neuroinflammation is a hallmark of various neurodegenerative disorders, yet effective treatments remain limited. This study investigates the neuroprotective potential of a cannabidiol (CBD)‐Rich Cannabis sativa L. (CS) extract in a lipopolysaccharide (LPS)‐induced neuroinflammation mouse model. The effects on anxiety‐like behavior, cognitive function, and locomotor activity were assessed using behavioral tests (open field, elevated plus maze, novel object recognition, and Morris water maze). Antioxidant activity was measured by assaying glutathione (GSH) levels and lipid peroxidation by‐products (TBARs). Anti‐inflammatory properties were evaluated using quantitative reverse transcription polymerase chain reaction (QRt‐PCR) for proinflammatory cytokines (IL‐6 and TNF‐α), glial fibrillary acidic protein (GFAP), and cannabinoid receptor 1 (CB1) mRNAs in the prefrontal cortex (PFC). Astrocytic bioenergetics were analyzed using extracellular flux assays. Additionally, computational inference with a deep learning approach was conducted to evaluate the synergistic interactions among CS phytocompounds on the CB1 receptors. Compared with synthetic CBD, the CS extract (20.0 mg/kg) demonstrated superior efficacy in mitigating LPS‐induced anxiety‐like behavior, cognitive deficits, and locomotor impairments. It also significantly mitigated oxidative stress (increased GSH, reduced TBARs) and suppressed proinflammatory cytokines and GFAP mRNAs, indicating potent anti‐inflammatory properties. The extract modulated CB1 receptor expression and preserved metabolic homeostasis in cortical astrocytes, preventing their shift from glycolysis to oxidative phosphorylation under neuroinflammatory conditions. Computational modeling highlighted conformational changes in CB1 receptor residues induced by Delta‐9‐THC that enhanced CBD binding. These findings underscore the potential of CS extract as a therapeutic candidate for managing neuroinflammation and its associated neurodegenerative consequences, warranting further clinical exploration.
- 8 April 2025
- Published by Wiley in Journal of Neuroscience Research
- Vol. 103 (4) , e70035
Cannabidiol‐Rich Cannabis sativa L. Extract Alleviates LPS‐Induced Neuroinflammation Behavioral Alterations, and Astrocytic Bioenergetic Impairment in Male Mice
Neuroinflammation is a hallmark of various neurodegenerative disorders, yet effective treatments remain limited. This study investigates the neuroprotective potential of a cannabidiol (CBD)‐Rich Cannabis sativa L. (CS) extract in a lipopolysaccharide (LPS)‐induced neuroinflammation mouse model. The effects on anxiety‐like behavior, cognitive function, and locomotor activity were assessed using behavioral tests (open field, elevated plus maze, novel object recognition, and Morris water maze). Antioxidant activity was measured by assaying glutathione (GSH) levels and lipid peroxidation by‐products (TBARs). Anti‐inflammatory properties were evaluated using quantitative reverse transcription polymerase chain reaction (QRt‐PCR) for proinflammatory cytokines (IL‐6 and TNF‐α), glial fibrillary acidic protein (GFAP), and cannabinoid receptor 1 (CB1) mRNAs in the prefrontal cortex (PFC). Astrocytic bioenergetics were analyzed using extracellular flux assays. Additionally, computational inference with a deep learning approach was conducted to evaluate the synergistic interactions among CS phytocompounds on the CB1 receptors. Compared with synthetic CBD, the CS extract (20.0 mg/kg) demonstrated superior efficacy in mitigating LPS‐induced anxiety‐like behavior, cognitive deficits, and locomotor impairments. It also significantly mitigated oxidative stress (increased GSH, reduced TBARs) and suppressed proinflammatory cytokines and GFAP mRNAs, indicating potent anti‐inflammatory properties. The extract modulated CB1 receptor expression and preserved metabolic homeostasis in cortical astrocytes, preventing their shift from glycolysis to oxidative phosphorylation under neuroinflammatory conditions. Computational modeling highlighted conformational changes in CB1 receptor residues induced by Delta‐9‐THC that enhanced CBD binding. These findings underscore the potential of CS extract as a therapeutic candidate for managing neuroinflammation and its associated neurodegenerative consequences, warranting further clinical exploration.
- Open Access
- 28 August 2024
- Published by Wiley
Cannabidiol-rich Cannabis sativa L. Extract Alleviates LPS-Induced Neuroinflammation in Male Mice: Computational Inference with Deep Learning Approach
Neuroinflammation is a hallmark of various neurodegenerative disorders, yet effective treatments remain limited. This study investigates the neuroprotective potential of a Cannabis sativa L. (C.S) extract rich in cannabidiol (CBD) and containing THC, CBG, THCV, and β-caryophyllene in a lipopolysaccharide (LPS)-induced neuroinflammation Male mice model. The effects on anxiety-like behavior, cognitive function, and locomotor activity were assessed using behavioral tests (open field, elevated plus maze, novel object recognition, and Morris water maze). Antioxidant activity was measured by assaying glutathione (GSH) levels and lipid peroxidation by-products (TBARs). Anti-inflammatory properties were evaluated using quantitative reverse transcription polymerase chain reaction (QRt-PCR) for proinflammatory cytokines (IL-6 and TNF-α), glial fibrillary acidic protein (GFAP), and cannabinoid receptor 1 (CB1) mRNAs in the prefrontal cortex (PFC). Additionally, the metabolic activity of cortical astrocytes was assessed. Compared to synthetic CBD, the C.S extract (20.0 mg/kg) demonstrated superior efficacy in attenuating LPS-induced anxiety-like behavior, cognitive decline, and locomotor impairments. It also significantly mitigated oxidative stress (increased GSH, reduced TBARs) and suppressed pro-inflammatory cytokines and GFAP mRNAs, indicating potent anti-inflammatory properties. The extract modulated CB1 receptor expression and preserved metabolic homeostasis in cortical astrocytes, preventing their shift from glycolysis to oxidative phosphorylation under neuroinflammatory conditions. Deep learning approaches revealed that Delta-9-THC’s conformational change at residues Phe200 and Trp356 in the CB1 receptor synergistically enhances CBD’s effect. These findings highlight the therapeutic potential of C.S extract for managing neuroinflammatory disorders, warranting further investigation into its clinical applications and underlying mechanisms
- 28 August 2024
- Published by Wiley
Open AccessCannabidiol-rich Cannabis sativa L. Extract Alleviates LPS-Induced Neuroinflammation in Male Mice: Computational Inference with Deep Learning Approach
Neuroinflammation is a hallmark of various neurodegenerative disorders, yet effective treatments remain limited. This study investigates the neuroprotective potential of a Cannabis sativa L. (C.S) extract rich in cannabidiol (CBD) and containing THC, CBG, THCV, and β-caryophyllene in a lipopolysaccharide (LPS)-induced neuroinflammation Male mice model. The effects on anxiety-like behavior, cognitive function, and locomotor activity were assessed using behavioral tests (open field, elevated plus maze, novel object recognition, and Morris water maze). Antioxidant activity was measured by assaying glutathione (GSH) levels and lipid peroxidation by-products (TBARs). Anti-inflammatory properties were evaluated using quantitative reverse transcription polymerase chain reaction (QRt-PCR) for proinflammatory cytokines (IL-6 and TNF-α), glial fibrillary acidic protein (GFAP), and cannabinoid receptor 1 (CB1) mRNAs in the prefrontal cortex (PFC). Additionally, the metabolic activity of cortical astrocytes was assessed. Compared to synthetic CBD, the C.S extract (20.0 mg/kg) demonstrated superior efficacy in attenuating LPS-induced anxiety-like behavior, cognitive decline, and locomotor impairments. It also significantly mitigated oxidative stress (increased GSH, reduced TBARs) and suppressed pro-inflammatory cytokines and GFAP mRNAs, indicating potent anti-inflammatory properties. The extract modulated CB1 receptor expression and preserved metabolic homeostasis in cortical astrocytes, preventing their shift from glycolysis to oxidative phosphorylation under neuroinflammatory conditions. Deep learning approaches revealed that Delta-9-THC’s conformational change at residues Phe200 and Trp356 in the CB1 receptor synergistically enhances CBD’s effect. These findings highlight the therapeutic potential of C.S extract for managing neuroinflammatory disorders, warranting further investigation into its clinical applications and underlying mechanisms
- 2 October 2023
- Published by Springer Nature in Neurotoxicity Research
- Vol. 41 (6) , 615-626
Effect of Cannabidiol in LPS-Induced Toxicity in Astrocytes: Possible Role for Cannabinoid Type-1 Receptors
Cerebral metabolic abnormalities are common in neurodegenerative diseases. Previous studies have shown that mitochondrial damage alters ATP production and increases reactive oxygen species (ROS) release which may contribute to neurodegeneration. In the present study, we investigated the neuroprotective effects of cannabidiol (CBD), a non-psychoactive component derived from marijuana (Cannabis sativa L.), on astrocytic bioenergetic balance in a primary cell culture model of lipopolysaccharide (LPS)-induced neurotoxicity. Astrocytic metabolic profiling using an extracellular flux analyzer demonstrated that CBD decreases mitochondrial proton leak, increased spare respiratory capacity and coupling efficiency in LPS-stimulated astrocytes. Simultaneously, CBD increased astrocytic glycolytic capacity and glycolysis reserve in a cannabinoid receptor type 1 (CB1)-dependent manner. CBD-restored metabolic changes were correlated with a significant decrease in the pro-inflammatory cytokines tumor necrosis factor α (TNFα) and interleukin-6 (IL-6) concentration and reduction of ROS production in LPS-stimulated astrocytes. These results suggest that CBD may inhibit LPS-induced metabolic impairments and inflammation by enhancing astrocytic metabolic glycolysis versus oxidative phosphorylation through its action on CB1 receptors. The present findings suggest CBD as a potential anti-inflammatory treatment in metabolic pathologies and highlight a possible role for the cannabinoidergic system in the modulation of mitochondrial oxidative stress. Graphical Abstract CBD enhances mitochondrial bioenergetic profile, attenuates proinflammatory cytokines release, and ROS overproduction of astrocytes stimulated by LPS. These effects are not mediated directly by CB1 receptors, while these receptors seem to have a key role in the anti-inflammatory response of the endocannabinoid system on astrocytes, as their specific inhibition by SR141716A led to increased pro-inflammatory cytokines release and ROS production. The graphical abstract is created with BioRender.com.
- 2 October 2023
- Published by Springer Nature in Neurotoxicity Research
- Vol. 41 (6) , 615-626
Effect of Cannabidiol in LPS-Induced Toxicity in Astrocytes: Possible Role for Cannabinoid Type-1 Receptors
Cerebral metabolic abnormalities are common in neurodegenerative diseases. Previous studies have shown that mitochondrial damage alters ATP production and increases reactive oxygen species (ROS) release which may contribute to neurodegeneration. In the present study, we investigated the neuroprotective effects of cannabidiol (CBD), a non-psychoactive component derived from marijuana (Cannabis sativa L.), on astrocytic bioenergetic balance in a primary cell culture model of lipopolysaccharide (LPS)-induced neurotoxicity. Astrocytic metabolic profiling using an extracellular flux analyzer demonstrated that CBD decreases mitochondrial proton leak, increased spare respiratory capacity and coupling efficiency in LPS-stimulated astrocytes. Simultaneously, CBD increased astrocytic glycolytic capacity and glycolysis reserve in a cannabinoid receptor type 1 (CB1)-dependent manner. CBD-restored metabolic changes were correlated with a significant decrease in the pro-inflammatory cytokines tumor necrosis factor α (TNFα) and interleukin-6 (IL-6) concentration and reduction of ROS production in LPS-stimulated astrocytes. These results suggest that CBD may inhibit LPS-induced metabolic impairments and inflammation by enhancing astrocytic metabolic glycolysis versus oxidative phosphorylation through its action on CB1 receptors. The present findings suggest CBD as a potential anti-inflammatory treatment in metabolic pathologies and highlight a possible role for the cannabinoidergic system in the modulation of mitochondrial oxidative stress. Graphical Abstract CBD enhances mitochondrial bioenergetic profile, attenuates proinflammatory cytokines release, and ROS overproduction of astrocytes stimulated by LPS. These effects are not mediated directly by CB1 receptors, while these receptors seem to have a key role in the anti-inflammatory response of the endocannabinoid system on astrocytes, as their specific inhibition by SR141716A led to increased pro-inflammatory cytokines release and ROS production. The graphical abstract is created with BioRender.com.